The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
The company raised net proceeds of $12.2 million, which it will use for various purposes, including working capital and payment of legacy obligations.
The firm said it will use the proceeds for working capital, trade payables, payment of legacy obligations, and general corporate purposes.
The company said in an SEC document that it will offer about 6.3 million shares of its common stock. Some purchasers would also be able to buy prefunded warrants.
The company will provide its molecular thyroid tests to researchers at Einstein Medical Center of Philadelphia.
Interpace shares were up 17 percent in early morning trading on the Nasdaq, as it reported a profitable quarter compared to a loss in the prior-year quarter.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.